Literature DB >> 31186253

Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis.

Shiney Seo1, Corey Smith2, Christopher Fraser3, Rajan Patheja1, Shaheen P Shah1,4, Sweera Rehan5, Pauline Crooks5, Michelle A Neller5, Rajiv Khanna5.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31186253      PMCID： PMC6560354          DOI： 10.1182/bloodadvances.2019000121

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  20 in total

1.  Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon- gamma and interleukin-2 and have a CD8+ cell early maturational phenotype.

Authors:  Elizabeth Sinclair; Qi Xuan Tan; Margaret Sharp; Valerie Girling; Chungkee Poon; Mark Van Natta; Douglas A Jabs; Margaret Inokuma; Holden T Maecker; Barry Bredt; Mark A Jacobson
Journal:  J Infect Dis       Date:  2006-10-26       Impact factor: 5.226

2.  Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.

Authors:  N Tormo; C Solano; I Benet; M A Clari; J Nieto; R de la Cámara; J López; N López-Aldeguer; J C Hernández-Boluda; M J Remigia; A Garcia-Noblejas; C Gimeno; D Navarro
Journal:  Bone Marrow Transplant       Date:  2009-07-20       Impact factor: 5.483

Review 3.  Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation.

Authors:  Jose F Camargo; Krishna V Komanduri
Journal:  Hematol Oncol Stem Cell Ther       Date:  2017-06-14

4.  Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections.

Authors:  Lei Bao; Morton J Cowan; Kimberly Dunham; Biljana Horn; Joseph McGuirk; Andrew Gilman; Kenneth G Lucas
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

5.  Autologous Adoptive T-cell Therapy for Recurrent or Drug-resistant Cytomegalovirus Complications in Solid Organ Transplant Recipients: A Single-arm Open-label Phase I Clinical Trial.

Authors:  Corey Smith; Leone Beagley; Sweera Rehan; Michelle A Neller; Pauline Crooks; Matthew Solomon; Chien-Li Holmes-Liew; Mark Holmes; Scott C McKenzie; Peter Hopkins; Scott Campbell; Ross S Francis; Daniel C Chambers; Rajiv Khanna
Journal:  Clin Infect Dis       Date:  2019-02-01       Impact factor: 9.079

6.  Treatment of cytomegalovirus retinitis with cytomegalovirus-specific T-lymphocyte infusion.

Authors:  Mrinali Patel Gupta; Peter Coombs; Susan E Prockop; Aisha A Hasan; Ekatarina Doubrovina; Richard J O'Reilly; Stuart H Cohen; Susanna S Park; Szilárd Kiss
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-01       Impact factor: 1.300

7.  Cytomegalovirus and the eye.

Authors:  A Carmichael
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

8.  Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity.

Authors:  Michael Boeckh; Wendy Leisenring; Stanley R Riddell; Raleigh A Bowden; Meei-Li Huang; David Myerson; Terry Stevens-Ayers; Mary E D Flowers; Terri Cunningham; Lawrence Corey
Journal:  Blood       Date:  2002-09-12       Impact factor: 22.113

9.  Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.

Authors:  Oriol Manuel; Shahid Husain; Deepali Kumar; Carlos Zayas; Steve Mawhorter; Marilyn E Levi; Jayant Kalpoe; Luiz Lisboa; Leticia Ely; Daniel R Kaul; Brian S Schwartz; Michele I Morris; Michael G Ison; Belinda Yen-Lieberman; Anthony Sebastian; Maha Assi; Atul Humar
Journal:  Clin Infect Dis       Date:  2012-11-29       Impact factor: 9.079

10.  Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.

Authors:  Siok-Keen Tey; Glen A Kennedy; Deborah Cromer; Miles P Davenport; Susan Walker; Linda I Jones; Tania Crough; Simon T Durrant; James A Morton; Jason P Butler; Ashish K Misra; Geoffrey R Hill; Rajiv Khanna
Journal:  PLoS One       Date:  2013-10-11       Impact factor: 3.240
View more
  3 in total

1.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

Review 2.  Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients?

Authors:  Estéfani García-Ríos; Marcos Nuévalos; Francisco J Mancebo; Pilar Pérez-Romero
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

3.  'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.

Authors:  Debottam Sinha; Sriganesh Srihari; Kirrliee Beckett; Laetitia Le Texier; Matthew Solomon; Archana Panikkar; George R Ambalathingal; Lea Lekieffre; Pauline Crooks; Sweera Rehan; Michelle A Neller; Corey Smith; Rajiv Khanna
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.